Trihexyphenidyl: Drug information

For additional information see "Trihexyphenidyl: Patient drug information" and "Trihexyphenidyl: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

Pharmacologic Category

Anti-Parkinson Agent, Anticholinergic;
Anticholinergic Agent

Dosing: Adult

Extrapyramidal symptoms, medication induced

Extrapyramidal symptoms (eg, dystonia and parkinsonism), medication induced (treatment):

Note: Anticholinergic agents are not recommended for the treatment of akathisia or tardive dyskinesia (Ref). Duration of therapy is based on the severity of EPS reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects), and patient risk factors (Ref). Some experts recommend attempting taper and discontinuation after several weeks to months (Ref).

Oral: Initial: 1 mg/day; increase as necessary to usual range: 5 to 15 mg/day in 3 to 4 divided doses.

Parkinsonism

Parkinsonism: Oral: Initial: 1 mg/day, increase by 2 mg increments at intervals of 3 to 5 days; usual dose: 6 to 10 mg/day in 3 to 4 divided doses; doses of 12 to 15 mg/day may be required. Consider dosage reduction when used concomitantly with levodopa, the usual dose of each may need to be reduced. Usual range: 3 to 6 mg/day in divided doses.

Discontinuation of therapy: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome, exacerbation of parkinsonism, and withdrawal symptoms (eg, palpitations, headache, insomnia, fainting, and nausea (Ref)). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Older Adult

Avoid use (Ref).

Dosing: Pediatric

(For additional information see "Trihexyphenidyl: Pediatric drug information")

Dystonia

Dystonia: Limited data available, efficacy results variable (Ref): Children and Adolescents: Oral: Initial: 0.1 to 0.2 mg/kg/dayin 2 to 3 divided doses; after the first week, titrate weekly or every 2 weeks as tolerated (eg, increase by 0.15 mg/kg/day or increase by 10% to 20%); usual maximum reported daily dose: 0.75 mg/kg/day in two or three divided doses or 60 mg/day (Ref). Higher weight-directed doses up to 2.6 mg/kg/day with a maximum daily dose of 80 mg/day have been described (Ref); relative to adult patients, data suggest that children and adolescents generally require higher doses for a therapeutic response (Ref).

Sialorrhea

Sialorrhea: Limited data available; dosage regimens variable: Children and Adolescents: Initial: 0.1 mg/kg/day in two divided doses; alternatively, an initial fixed-dose regimen in children ≥3 years and adolescents of 1 mg twice daily has also been described; titrate every 2 weeks in 10% to 20% increments (Ref). In sialorrhea trials, a final fixed-dose regimen of 2 mg twice or three times daily has been reported (Ref); a retrospective trial that included a mixed patient population evaluating both sialorrhea and dystonia and trihexyphenidyl use reported a mean maximum daily dose: 0.55 mg/kg/day in divided doses (range: 0.03 to 3.13 mg/kg/day) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Gastrointestinal: Nausea (30% to 50%), xerostomia (30% to 50%)

Nervous system: Dizziness (30% to 50%), nervousness (30% to 50%)

Ophthalmic: Blurred vision (30% to 50%)

Postmarketing:

Cardiovascular: Paradoxical bradycardia (sinus bradycardia) (Blumensohn 1986), tachycardia

Dermatologic: Erythema of skin (Zhao 2022), hypohidrosis (Zhao 2022), skin rash, xeroderma

Endocrine & metabolic: SIADH (Zhao 2022)

Gastrointestinal: Constipation (Zhao 2022), paralytic ileus, toxic megacolon, vomiting (Zhao 2022)

Genitourinary: Urinary hesitancy, urinary retention (Zhao 2022)

Nervous system: Anxiety (Zhao 2022), asthenia, choreiform movements (Warne 1979, cognitive dysfunction (including confusion and memory impairment) (Zhao 2022), delusion, drowsiness, euphoria (Jellinek 1977), hallucination (Zhao 2022), headache, myasthenia gravis (Ueno 1987), neuroleptic malignant syndrome (with abrupt withdrawal), paranoid ideation

Neuromuscular & skeletal: Dyskinesia (including tardive dyskinesia [orobuccal] (Hauser 1993, Zhao 2022)

Ophthalmic: Angle-closure glaucoma (including blindness), cycloplegia, increased intraocular pressure, mydriasis

Miscellaneous: High fever (Zhao 2022), malignant hyperthermia (Zhao 2022)

Contraindications

Hypersensitivity to trihexyphenidyl or any component of the formulation; narrow angle glaucoma.

Warnings/Precautions

Concerns related to adverse effects:

• Anhidrosis/hyperthermia: May cause anhidrosis and hyperthermia. Severe anhidrosis and fatal hyperthermia have occurred; use with caution in hot weather or during exercise, especially when administered concomitantly with other anticholinergic drugs to chronically ill patients, patients with alcohol use disorder, patients with CNS disease, or persons doing manual labor in a hot environment.

• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); monitor patients requiring long-term use.

• CNS depression: May impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Ocular effects: May precipitate angle closure with an increase in intraocular pressure. If blurring of vision occurs, consider the possibility of narrow angle glaucoma; blindness because of aggravation of narrow angle glaucoma has been reported.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension.

• GI obstruction: Use with caution in patients with obstructive disease of the GI tract.

• Glaucoma: Use with caution in patients with glaucoma; blindness after long-term use due to narrow angle glaucoma has been reported.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.

• Psychiatric effects: May impair memory and further exacerbate cognitive deficits in elderly patients; in high doses may cause confusion, delirium, and hallucinations (Holloman 1997; Tonda 1994).

• Renal impairment: Use with caution in patients with renal impairment.

• Tardive dyskinesia: Not recommended for use in patients with tardive dyskinesia unless concomitant Parkinson disease or tardive dystonia exists (Kang 1986); trihexyphenidyl does not relieve symptoms of tardive dyskinesia and may potentially exacerbate symptoms.

Other warnings/precautions:

• Discontinuation of therapy: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome (NMS), exacerbation of Parkinsonism, and withdrawal symptoms including tension, irritability, perspiration, palpitations, headache, insomnia, abdominal distress, anorexia, faint or choking feelings, nausea, and photophobia (McInnis 1985). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (Manos 1981a; Manos 1981b).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral:

Generic: 0.4 mg/mL (473 mL)

Tablet, Oral, as hydrochloride:

Generic: 2 mg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Trihexyphenidyl HCl Oral)

0.4 mg/mL (per mL): $0.11

Tablets (Trihexyphenidyl HCl Oral)

2 mg (per each): $0.18 - $0.55

5 mg (per each): $0.36 - $1.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as hydrochloride:

Generic: 2 mg, 5 mg

Administration: Adult

Oral: May be administered before or after meals (if excessive dry mouth develops, consider administering before meals unless it causes nausea; postencephalitic patients who are prone to excessive salivation may prefer to take after meals); tolerated best if given in 3 daily doses and with food. High doses (>10 mg/day) may be divided into 4 doses (at each meal and at bedtime).

Administration: Pediatric

Oral: Administer before or after meals; if excessive dry mouth develops, consider administering before meals unless it causes nausea; best tolerated when administered in 3 daily doses and with food.

Use: Labeled Indications

Extrapyramidal symptoms, medication-induced (treatment): Management of medication-induced extrapyramidal symptoms.

Parkinsonism: Adjunctive therapy in the treatment of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic).

Medication Safety Issues

Sound-alike/look-alike issues:

Trihexyphenidyl may be confused with trifluoperazine

Older adult: High-Risk Medication:

Beers Criteria: Trihexyphenidyl is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its highly anticholinergic properties. It is not recommended for the prevention or treatment of extrapyramidal symptoms with antipsychotics. In the treatment of Parkinson disease, more effective agents are available (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Acrivastine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Amantadine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benztropine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Benztropine. Risk C: Monitor

Biperiden: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Biperiden. Risk C: Monitor

Bornaprine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Bromperidol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bromperidol. Risk C: Monitor

Buclizine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Buclizine. Risk C: Monitor

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Chlorprothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Chlorprothixene. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

CloZAPine: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

Cyclizine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Darifenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Darifenacin. Risk C: Monitor

Dicyclomine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dicyclomine. Risk C: Monitor

Dimethindene (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dimethindene (Systemic). Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

Fesoterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Fesoterodine. Risk C: Monitor

FluPHENAZine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrrolate (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Systemic). Risk C: Monitor

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Lisuride: Trihexyphenidyl may increase adverse/toxic effects of Lisuride. Risk X: Avoid

Maprotiline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Maprotiline. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Metergoline: May increase adverse/toxic effects of Anticholinergic Anti-Parkinsonian Agents. Risk C: Monitor

Methotrimeprazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methotrimeprazine. Risk C: Monitor

Methscopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methscopolamine. Risk C: Monitor

Mirabegron: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Mirabegron. Risk C: Monitor

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

OLANZapine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OLANZapine. Risk C: Monitor

Opioid Agonists: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor

Opipramol: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

OxyBUTYnin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OxyBUTYnin. Risk C: Monitor

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Perphenazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Perphenazine. Risk C: Monitor

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Promethazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Promethazine. Risk C: Monitor

Propantheline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Propantheline. Risk C: Monitor

Propiverine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

QuiNIDine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Scopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Scopolamine. Risk C: Monitor

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thiothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Thiothixene. Risk C: Monitor

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tolterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tolterodine. Risk C: Monitor

Topiramate: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Topiramate. Risk C: Monitor

Tricyclic Antidepressants: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tricyclic Antidepressants. Risk C: Monitor

Trimethobenzamide: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trimethobenzamide. Risk C: Monitor

Trospium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trospium. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Zuclopenthixol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Zuclopenthixol. Risk C: Monitor

Pregnancy Considerations

Animal reproduction studies have not been conducted. One case report did not show evidence of adverse events after trihexyphenidyl administration during pregnancy (Robottom 2011).

Breastfeeding Considerations

It is not known if trihexyphenidyl is present in breast milk. The manufacturer recommends that caution be exercised when administering trihexyphenidyl to patients who are breastfeeding. Anticholinergic agents may suppress lactation.

Dietary Considerations

May be taken before or after meals; tolerated best if given with food.

Monitoring Parameters

Gonioscopic evaluations (prior to therapy initiation); IOP (periodically); anticholinergic adverse reactions for patients on long-term therapy (as clinically indicated).

Mechanism of Action

Exerts a direct inhibitory effect on the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly on the muscle itself and indirectly through parasympathetic nervous system (inhibitory effect)

Pharmacokinetics (Adult Data Unless Noted)

Metabolism: Hydroxylation of the alicyclic groups (Brocks 1999)

Half-life elimination: 33 hours (Brocks 1999)

Time to peak, serum: 1.3 hours (Brocks 1999)

Excretion: Urine and bile (Brocks 1999)

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Apo trihex | Artane | Trihexyphenidyl;
(AR) Argentina: Artane | Trihexifenidilo;
(AT) Austria: Artane;
(AU) Australia: Artane;
(BD) Bangladesh: Delpark | Heximax | Hexinor | Hexiphen | Hexirest | Parkifen | Parkitrol | Perkinor | Tridyl | Trihexy | Tripar;
(BE) Belgium: Artane;
(BG) Bulgaria: Parcisol | Parkisan;
(BR) Brazil: Artane | Triexidyl;
(CH) Switzerland: Artane;
(CL) Chile: Artane | Tenvatil | Tonaril;
(CN) China: An tan | Artane | Benzhexol | Benzhexol hydrochloride | Trihexyphenidyl;
(CO) Colombia: Artane | Trihexifenidilo;
(CZ) Czech Republic: Artane;
(DE) Germany: Artane | Parkopan;
(DO) Dominican Republic: Artane | Tremol | Tremolin;
(EE) Estonia: Cyclodol | Parkopan;
(EG) Egypt: Parkinol;
(ES) Spain: Artane;
(FI) Finland: Artane;
(FR) France: Artane | Trihexyphenidyl richard;
(GB) United Kingdom: Agitane | Artane | Bentex | Benzhexol | Benzhexol dc | Broflex | Broflex bms | Trihexyphenidy | Trihexyphenidyl;
(GR) Greece: Artane | Benzhexol;
(HK) Hong Kong: Adtendyl | Apo trihex | Artandyl | Artane | Benzhexol;
(ID) Indonesia: Arkicel | Arkine | Artane | Hexymer | Parkinal | Trihexyphenidyl;
(IE) Ireland: Artane | Broflex;
(IL) Israel: Artane | Partane | Rodenal;
(IN) India: Antichol | Barohexy | Benz | Bexol | Dyskinil | Dystonil | Ecitane | Emelaxy | Epsinil | Hex | Hexylent | Lahexy | Manohexy | Maphyl | Matcalm | Pacitane | Parkin | Parkinta | Parkitane | Parnil | Parnon | Relihexy | Tanzee | Thp | Tri ex | Triden | Trihexy | Trikotame | Triphen | Trit 2 | Tryal | Xydyl;
(IQ) Iraq: Samhexol;
(IT) Italy: Artane;
(JO) Jordan: Artane | Parkizole;
(JP) Japan: Artane | Parkines towa | Parkiness merck hoei | Parkisonal | Pyramistin | Sedrena | Stobrun | Topcron | Tremin | Trihexin | Trihexyphenidyl Hcl Nipro | Triphedinon;
(KE) Kenya: Benzhexol | Parkin;
(KR) Korea, Republic of: Artane | Trihexin | Trihexyne | Trihexyphenidyl hydrochlorid;
(KW) Kuwait: Artane;
(LB) Lebanon: Artane | Benzhexol;
(LT) Lithuania: Cyclodol | Parkisan | Parkopan | Triphen | Triphenidyl;
(LU) Luxembourg: Artane;
(LV) Latvia: Artane | Cyclodol | Parkisan | Parkopan | Triphenidyl;
(MA) Morocco: Artane;
(MX) Mexico: Artane | Hipokinon | Trihexifenidilo;
(MY) Malaysia: Aca | Apo trihex | B-Hex | Benzhexol | Pharmaniaga benzhexol | Uphazhexol;
(NG) Nigeria: Axzol | Babazole | Benzhexol | Cinnamon benzhexol | Embazol | Oxazol | Pbenz | Royale benzhexol;
(NL) Netherlands: Artane;
(NO) Norway: Artane | Trihexyphenidyl;
(NZ) New Zealand: Artane;
(PE) Peru: Artane;
(PH) Philippines: Artane;
(PK) Pakistan: Hexidyl | Pacitane;
(PL) Poland: Artane | Parkopan | Triphenidyl;
(PR) Puerto Rico: Artane | Trihexyphenidyl;
(PT) Portugal: Artane;
(PY) Paraguay: Desagit;
(RU) Russian Federation: Cyclodol | Parkopan | Romparkin | Trihexyphenidyl | Trihexyphenidyl ferein | Trihexyphenidyl organica | Trihexyphenidyl ph | Trihexyphenidyl pharmstandart | Triphen;
(SA) Saudi Arabia: Artane;
(SE) Sweden: Artane | Pargitan;
(SG) Singapore: Apo trihex | Artyl | B-Hex | Beahexol | Benzhexol;
(SI) Slovenia: Artane;
(SR) Suriname: Apo trihex | Trihexyphenidyl;
(TH) Thailand: Aca | Acamed | Artane | Benzhexol | Pozhexol | Tridyl;
(TN) Tunisia: Apo trihex | Artane | Parkizol;
(TW) Taiwan: Artane | Artine | Atan | B.h.l | Benzhexol | Benzox | Parkindyl | Partane | Switane;
(UA) Ukraine: Cyclodol | Parcopan | Parkopan | Trifen;
(UG) Uganda: Benzhexol;
(UY) Uruguay: Artane;
(ZA) South Africa: Artane | Benzhexol;
(ZM) Zambia: Benzhexol;
(ZW) Zimbabwe: Apo trihex

2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. J Child Neurol. 2011;26(7):810-816. [PubMed 21498790]
Blumensohn R, Razoni G, Shalev A, Munitz H. Bradycardia due to trihexyphenidyl hydrochloride. Drug Intell Clin Pharm. 1986;20(10):786-787. doi:10.1177/106002808602001012 [PubMed 3769769]
Brocks DR, “Anticholinergic Drugs Used in Parkinson's Disease: An Overlooked Class of Drugs From a Pharmacokinetic Perspective,” J Pharm Pharmaceut Sci, 1999, 2(2):39-46. [PubMed 10952768]
Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36(2):160-164. doi:10.1212/wnl.36.2.160 [PubMed 3511401]
Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. Pediatr Neurol. 2011;44(3):202-206. [PubMed 21310336]
Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol. 2012;26(9):1167-1174. doi:10.1177/0269881112447988 [PubMed 22651987]
Fehlings D, Brown L, Harvey A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev Med Child Neurol. 2018;60(4):356-366. doi:10.1111/dmcn.13652 [PubMed 29405267]
Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord. 1993;8(4):512-514. doi:10.1002/mds.870080417 [PubMed 8232363]
Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997:54(1):2461-2477. [PubMed 9359953]
Jellinek T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Syst. 1977;38(5):353-355. [PubMed 852367]
Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord. 1986;1(3):193-208. doi: 10.1002/mds.870010305. [PubMed 2904118]
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103. doi: 10.1093/schbul/sbp130. [PubMed 19955388]
Kumar S, Shankar Kaushik J, Verma S, Dabla S. Gabapentin as add-on therapy to trihexyphenidyl in children with dyskinetic cerebral palsy: a randomized, controlled trial. Indian J Pediatr. 2023;90(9):873-879. doi:10.1007/s12098-022-04265-2 [PubMed 35867274]
Lott E, Fehlings D, Gelineau-Morel R, et al. Physician approaches to the pharmacologic treatment of dystonia in cerebral palsy. Pediatrics. 2024;154(1):e2023065512. doi:10.1542/peds.2023-065512 [PubMed 38836309]
Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry. 1981a;138(2):184-188. [PubMed 6109453]
Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt? J Nerv Ment Dis. 1981b;169(10):659-661. [PubMed 6116743]
McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand. 1985;71(3):297-303. [PubMed 3984771]
Papandreou A, Mahony A, Breaks A, Absoud M, Fairhurst C. Comparative efficacy and side effect profiles of interventions for pediatric saliva control: a cohort study. J Pediatr. 2024;265:113803. doi:10.1016/j.jpeds.2023.113803 [PubMed 37898423]
Reddihough D, Johnson H, Staples M, Hudson I, Exarchos H. Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol. 1990;32(11):985-989. doi:10.1111/j.1469-8749.1990.tb08121.x [PubMed 2269408]
Rice J and Waugh MC, "Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy," Child Neurol, 2009, 24(2):176-82. [PubMed 19182155]
Robottom BJ and Reich SG, "Exposure to High Dosage Trihexyphenidyl During Pregnancy for Treatment of Generalized Dystonia: Case Report and Literature Review," Neurologist, 2011, 17(6):340-1. [PubMed 22045287]
Sanger TD, Bastian A, Brunstrom J, et al, "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy," J Child Neurol, 2007, 22(5):530-7. [PubMed 17690057]
Trihexyphenidyl hydrochloride tablets [prescribing information]. Buffalo Grove, IL: Pack Pharmaceuticals; June 2015.
Trihexyphenidyl hydrochloride oral solution [prescribing information]. Greenville, SC: Pai Pharmaceutical Associates; October 2010.
Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy. 1994;14(5):543-560. [PubMed 7997388]
Ueno S, Takahashi M, Kajiyama K, et al. Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology. 1987;37(5):832-833. doi:10.1212/wnl.37.5.832 [PubMed 3033545]
Warne RW, Gubbay SS. Choreiform movements induced by anticholinergic therapy. Med J Aust. 1979;1(10):465. [PubMed 470689]
You P, Strychowsky J, Gandhi K, Chen BA. Anticholinergic treatment for sialorrhea in children: a systematic review. Paediatr Child Health. 2021;27(2):82-87. doi:10.1093/pch/pxab051 [PubMed 35599670]
Zhao J, Xu G, Feng C, et al. Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: a case report. Medicine (Baltimore). 2020;99(20):e20129. doi:10.1097/MD.0000000000020129 [PubMed 32443324]

Topic 10022 Version 316.0

خرید پکیج

Trihexyphenidyl: Drug information